Cardiovascular; Tachycardia; Dermatological/Mucosal; Generalized urticaria(hives); Generalized erythema; Generalized Pruritus with skin rash/Generalized Pruritus without skin rash; Generalized prickle sensation; Localized injection site urticaria; Red and itchy eyes; Nausea; Tachypnoea; Dry cough; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 30 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in deltoid left, administration date 26Jan2022 (Lot number: FJ1614) at the age of 30 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "PCN" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Bnt162b2 (dose 1, site of injection: Left deltoid, Route: Intramuscular, COVID-19 vaccine name: Pfizer, Batch/Lot number: FJ1685), administration date: 19Dec2020, when the patient was 29 years old, for Covid-19 immunization; Bnt162b2 (dose 2, site of injection: Left deltoid, Route: Intramuscular, COVID-19 vaccine name: Pfizer, Batch/Lot number: FL3249), administration date: 28Jan2021, when the patient was 29 years old, for Covid-19 immunization. The following information was reported: CARDIOVASCULAR DISORDER (non-serious) with onset 26Jan2022, outcome "recovering", described as "Cardiovascular"; TACHYCARDIA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Tachycardia"; MUCOSAL DISORDER (non-serious) with onset 26Jan2022, outcome "recovering", described as "Dermatological/Mucosal"; URTICARIA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Generalized urticaria(hives)"; ERYTHEMA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Generalized erythema"; RASH (non-serious) with onset 26Jan2022, outcome "recovering", described as "Generalized Pruritus with skin rash/Generalized Pruritus without skin rash"; PARAESTHESIA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Generalized prickle sensation"; VACCINATION SITE URTICARIA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Localized injection site urticaria"; EYE PRURITUS (non-serious) with onset 26Jan2022, outcome "recovering", described as "Red and itchy eyes"; NAUSEA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Nausea"; TACHYPNOEA (non-serious) with onset 26Jan2022, outcome "recovering", described as "Tachypnoea"; COUGH (non-serious) with onset 26Jan2022, outcome "recovering", described as "Dry cough". Therapeutic measures were taken as a result of cardiovascular disorder, tachycardia, mucosal disorder, urticaria, erythema, rash, paraesthesia, vaccination site urticaria, eye pruritus, nausea, tachypnoea, cough.  Additional information: Anaphylactic reaction occurred less than 10 mins after injection. The patient required medical intervention which included Antihistamine. There was multi-organ involvement. The events required the initiation of new medication Claritin and Benadryl. The patient was not seen in the Emergency Department. The patient was not hospitalized and neither admitted to an Intensive Care Unit. History of allergy to PCN was reported. The patient was taking birth control medications prior to the event being reported. The patient did not receive any vaccines for any other conditions prior to the event reported. The patient did not receive any recent vaccines for SARS-CoV2 other than Pfizer-BioNTech COVID-19 Vaccine prior to event being reported. The patient did not receive any other vaccines around the time of Pfizer-BioNTech COVID-19 Vaccine vaccination.  No follow-up attempts are possible. No further information is expected.